Molecular and cellular adaptations to extended hypothermic oxygenated perfusion in donation-after-circulatory-death hearts in a porcine model - Takeaways - MDSpire

Molecular and cellular adaptations to extended hypothermic oxygenated perfusion in donation-after-circulatory-death hearts in a porcine model

  • By

  • Morgan K. Moroi

  • Yaagnik Kosuri

  • Cary Karcher

  • Diana Albino

  • Anthony Campbell

  • Arianna Adamo

  • Emre Bektik

  • Christine Chan

  • Kenmond Fung

  • Miroslav Sekulic

  • Shaheer K. Faruqi

  • Craig J. Goergen

  • Melissa Tamimi

  • Koji Takeda

  • Giovanni Ferrari

  • May 25, 2026

Share

  • 1

    Hypothermic oxygenated perfusion (HOPE) preserves cardiomyocyte viability and metabolic stability in porcine hearts after donation after circulatory death (DCD).

  • 2

    Extended HOPE for 24 hours maintains myocardial integrity, contrasting with complete loss of viability after 24 hours of static cold storage (SCS).

  • 3

    RNA sequencing and metabolomics indicate minimal transcriptional and metabolic shifts between hearts preserved by 2-hour SCS and 24-hour HOPE.

  • 4

    Normothermic regional perfusion (NRP) during procurement significantly enhances contractility and cardiomyocyte integrity compared to direct procurement without NRP.

  • 5

    This study highlights the potential of HOPE and NRP in improving outcomes for hearts procured from DCD donors, addressing organ shortage in transplantation.

Original Source(s)

Molecular and cellular adaptations to extended hypothermic oxygenated perfusion in donation-after-circulatory-death hearts in a porcine model

  • by Morgan K. Moroi, Yaagnik Kosuri, Cary Karcher, Diana Albino, Anthony Campbell, Arianna Adamo, Emre Bektik, Christine Chan, Kenmond Fung, Miroslav Sekulic, Shaheer K. Faruqi, Craig J. Goergen, Melissa Tamimi, Koji Takeda, Giovanni Ferrari

  • May 25, 2026

Related Content

Non-Invasive Testing for Coronary Artery Disease

Dr. Uprety discusses the current role of non-invasive testing for coronary artery disease, highlighting evidence-based diagnostic strategies and the appropriate use of imaging modalities to improve early detection, risk stratification, and clinical decision-making.

  • May 18, 2026

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

Non-Invasive Techniques In Pediatric Dyslipidemia

Damon B. Dixon, MD, at Phoenix Children’s Cardiology, is the author to this EndoText chapter. Dr. Dixon brings nationally recognized expertise in pediatric cardiovascular risk assessment and non?invasive vascular imaging.

  • by

  • May 15, 2026

  • 1 min